{"created":"2023-06-29T05:24:48.343832+00:00","id":2001594,"links":{},"metadata":{"_buckets":{"deposit":"f108d171-05ae-40f7-905e-482147c69596"},"_deposit":{"created_by":16,"id":"2001594","owner":"16","owners":[16],"pid":{"revision_id":0,"type":"depid","value":"2001594"},"status":"published"},"_oai":{"id":"oai:soar-ir.repo.nii.ac.jp:02001594","sets":["1942:1943:1944"]},"author_link":[],"item_14_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2023-03-31","bibliographicIssueDateType":"Issued"}}]},"item_14_date_granted_8":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2023-03-31"}]},"item_14_degree_grantor_10":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_name":"信州大学(Shinshu university)"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"13601","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_14_degree_name_9":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）"}]},"item_14_description_26":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"次の雑誌に発表。 /Biomedicines 10(7) :1667(2022); doi:10.3390/biomedicines10071667 © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).","subitem_description_type":"Other"}]},"item_14_description_37":{"attribute_name":"資源タイプ（コンテンツの種類）","attribute_value_mlt":[{"subitem_description":"Thesis","subitem_description_type":"Other"}]},"item_14_description_5":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"ZHANG ZHE. Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice（臨床投与相当量の新規選択的PPARαモジュレータ―・ペマフィブラートをマウスに投与すると、肝臓のPPARαに作用して血中の中性脂肪値が低下する）. 信州大学, 2023, 博士論文. 博士（医学）, 甲第1315号, 令和05年03月31日授与.","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_14_dissertation_number_7":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"13601甲第1315号"}]},"item_14_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.50928/0002001594","subitem_identifier_reg_type":"JaLC"}]},"item_14_publisher_4":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"信州大学"}]},"item_14_relation_54":{"attribute_name":"PubMed","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"35884970"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://pubmed.ncbi.nlm.nih.gov/35884970/","subitem_relation_type_select":"PMID"}}]},"item_14_relation_55":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.3390/biomedicines10071667"}],"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.3390/biomedicines10071667","subitem_relation_type_select":"DOI"}}]},"item_14_text_11":{"attribute_name":"学位の区分","attribute_value_mlt":[{"subitem_text_value":"doctoral"}]},"item_14_text_12":{"attribute_name":"学位の分野","attribute_value_mlt":[{"subitem_text_value":"医学"}]},"item_14_text_13":{"attribute_name":"学位の報告番号","attribute_value_mlt":[{"subitem_text_value":"甲第1315号"}]},"item_1627890986942":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_be7fb7dd8ff6fe43","subitem_version_type":"NA"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"ZHANG, ZHE","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available"}],"filename":"19HM123A_yoshi.pdf","format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"内容の要旨","url":"https://soar-ir.repo.nii.ac.jp/record/2001594/files/19HM123A_yoshi.pdf"},"version_id":"b9e037de-03d6-485b-a349-5803ba2de4a8"},{"accessrole":"open_access","date":[{"dateType":"Available"}],"filename":"19HM123A_shinsa.pdf","format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"審査結果の要旨","url":"https://soar-ir.repo.nii.ac.jp/record/2001594/files/19HM123A_shinsa.pdf"},"version_id":"09ba2865-ca7f-443a-aa73-57c93be4289e"},{"accessrole":"open_access","date":[{"dateType":"Available"}],"filename":"19HM123A_ronbun.pdf","format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"博士論文の全文","objectType":"fulltext","url":"https://soar-ir.repo.nii.ac.jp/record/2001594/files/19HM123A_ronbun.pdf"},"version_id":"943b5645-e613-4ed2-b18d-8eed044bce5f"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice（臨床投与相当量の新規選択的PPARαモジュレータ―・ペマフィブラートをマウスに投与すると、肝臓のPPARαに作用して血中の中性脂肪値が低下する）","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice（臨床投与相当量の新規選択的PPARαモジュレータ―・ペマフィブラートをマウスに投与すると、肝臓のPPARαに作用して血中の中性脂肪値が低下する）","subitem_title_language":"ja"}]},"item_type_id":"14","owner":"16","path":["1944"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-06-30"},"publish_date":"2023-06-30","publish_status":"0","recid":"2001594","relation_version_is_last":true,"title":["Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice（臨床投与相当量の新規選択的PPARαモジュレータ―・ペマフィブラートをマウスに投与すると、肝臓のPPARαに作用して血中の中性脂肪値が低下する）"],"weko_creator_id":"16","weko_shared_id":-1},"updated":"2023-06-29T07:01:26.363530+00:00"}